The World Health Organization has recommended that testing for high-risk human papillomavirus (HPV) (hrHPV) infection be incorporated into cervical screening programs in all settings worldwide. In many high-burden, low-income countries, it will not be feasible to achieve high cervical screening coverage using hrHPV assays that require clinician-collected samples. We conducted the first evaluation of self-collected vaginal specimens compared with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. Women aged 30 to 54 years attending two well-woman clinics in Papua New Guinea were invited to participate and provided self-collected vaginal and clinician-collected cervical cytobrush specimens. Both specimen types were tested at the point of care by using the Xpert HPV test. Women were given their cervical test result the same day. Those with a positive hrHPV test and positive examination upon visual inspection of the cervix with acetic acid were offered same-day cervical cryotherapy. A total of 1,005 women were enrolled, with 124 (12.3%; 95% confidence interval [CI], 10.3%, 14.4%) being positive for any hrHPV infection. There was a 99.4% overall percent agreement (OPA) between vaginal and cervical tests for HPV-16 (95% CI, 98.9%, 99.9%), a 98.5% OPA for HPV-18/45 (95% CI, 97.7%, 99.3%), a 94.4% OPA for other hrHPV infections (95% CI, 92.9%, 95.9%), and a 93.4% OPA for all hrHPV types combined (95% CI, 91.8%, 95.0%). Self-collected vaginal specimens had excellent agreement with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. This approach provides for the first time an opportunity to incorporate point-of-care hrHPV testing into clinical cervical screening algorithms in high-burden, low-income settings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922075PMC
http://dx.doi.org/10.1128/JCM.00529-16DOI Listing

Publication Analysis

Top Keywords

xpert hpv
16
self-collected vaginal
16
clinician-collected cervical
16
hrhpv infection
16
cervical specimens
12
cervical screening
12
hpv test
12
cervical
10
hrhpv
9
human papillomavirus
8

Similar Publications

Background: We aimed to conduct an updated and comprehensive summary of the sensitivity and specificity of three human papillomavirus (HPV) point-of-care (POC) tests (careHPV™, oncoE6™ cervical test, Xpert® HPV) to guide resource-constrained countries for their implementation in cervical cancer screening.

Methods: Databases including Medline, Embase, Web of Science and cumulated index in nursing and allied health literature (CINAHL) were searched between January 2004 and October 2024. Observational studies analyzing the three tests for cervical cancer screening were included.

View Article and Find Full Text PDF
Article Synopsis
  • - In South Africa, a study focused on women living with HIV (WLHIV) found a high prevalence of high-risk HPV infections, with 67.3% testing positive, particularly HPV16 and HPV18/45 types being common.
  • - Many participants (91.3%) had never been screened for cervical cancer, and a significant portion (33.3%) showed abnormal cervical cytology results, strongly correlating this with HPV positivity.
  • - The research emphasizes the importance of early HIV diagnosis and treatment, as well as regular cervical cancer screenings, particularly for those with low CD4 cell counts, to reduce cervical cancer risks among WLHIV.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined the prevalence of high-risk HPV infections and genotype distribution in individuals with normal cervical cytology, along with their vaccination status.
  • A total of 110 cervical samples were tested using the Cepheid GeneXpert system, revealing that 33% were positive for HPV DNA, with HPV16 being the most common type found.
  • Most participants (96.4%) had not received any HPV vaccine, and the few vaccinated individuals still showed HPV infections, highlighting the need for greater public awareness regarding HPV risks.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates how effective a new rapid HPV test (ScreenFire) is compared to an established test (Xpert) in detecting HPV and cervical precancer in women living with HIV in Malawi, a country facing high cervical cancer rates and limited screening access due to costs.
  • - Researchers analyzed self- and provider-collected samples from 315 women, finding high agreement between the two tests, especially in self-collected specimens, with ScreenFire being positive in 90% of cases that Xpert identified as HPV-positive.
  • - The results revealed that among the samples tested, a significant portion of women had normal pathology, while a smaller percentage showed varying degrees of cervical precancer, demonstrating the potential of the ScreenFire test as an effective
View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of two HPV testing methods (ScreenFire and Xpert) for screening cervical cancer among women living with HIV in Malawi, a region heavily affected by cervical cancer yet lacking affordable screening options.
  • Researchers analyzed 315 samples collected from both self and healthcare providers, finding that the two tests agreed significantly in detecting HPV positivity and identifying precancerous conditions.
  • ScreenFire showed a strong ability to consistently identify higher-grade lesions (CIN2+) without missing any significant cases when compared to the Xpert method.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!